58886-81-0

Upstream product

• 107-13-1 acrylonitrile 
• 2043-61-0 cyclohexanecarbaldehyde 
• 53188-66-2 N-(cyclohexylmethylene)-2-methylpropan-2-amine 

Downstream Products

• 180-48-3 2-azaspiro<5,5>undecane 
• 67625-75-6 1-(2-cyanoethyl)-1-(1,3-dioxolanyl)cyclohexane 
• 29671-90-7 3-(1-(hydroxymethyl)cyclohexyl)propanenitrile 
• 105599-49-3 N-(2-azaspiro 5,5 undecanyl)-N'-phenylurea 
• 632329-09-0 C₆₃H₇₆N₄O₁₁S 
• 632329-10-3 C₆₃H₇₆N₄O₁₁S 
• 632328-97-3 1-[tert-butyl-dimethylsilyloxymethyl]-1-(2-cyanoethyl)-cyclohexane 
• 632329-00-1 1-[tert-butyldimethylsilyloxymethyl]-1-(3-propanalyl)-cyclohexane 
• 713510-61-3 4-benzyloxy-N-[3-(1-[1,3]dioxolan-2-yl-cyclohexyl)-propyl]-3-hydroxy-butyramide 
• 105599-56-2 3-(1-[1,3]Dioxolan-2-yl-cyclohexyl)-propylamine 

Relevant academic research and scientific papers

A stannous chloride-induced deacetalisation-cyclisation process to prepare the ABC ring system of 'upenamide

A stannous chloride-induced deacetalisation-cyclisation approach to the ABC core of the macrocyclic alkaloid, 'upenamide is reported. The use of a substituted β-lactone to prepare a C-2 substituted 'upenamide analogue is also disclosed.

Inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Azaspiro compounds

This invention relates to a method of using compounds selected from those of the following formula : STR1 wherein R1 is hydrogen, alkyl or alkenyl; R2 is hydrogen, alkyl, cycloalkyl or mononuclear aryl or R1 and R2/s